Korean Journal of Clinical Pharmacy

Table. 2. Table 2

Frequency analysis of ADE reports for cancer immunotherapy agents

Drug	Frequency	Top 3 Adverse Events†			Percent	Marketing Year	Per-Year AE Report*

		1	2	3
sorafenib	20,060	205	1,765	268	28.21	2008	1,824
afatinib	6,417	205	27	327	9.03	2014	1,283
pazopanib	4,755	205	165	268	6.69	2010	528
cetuximab	5,180	27	1	308	7.29	2009	518
rituximab	8,245	572	24	731	11.60	2003	515
nilotinib	3,187	594	27	24	4.48	2010	354
lapatinib	4,054	1,765	205	308	5.70	2007	338
imatinib	3,669	308	27	544	5.16	2006	282
regorafenib	1,556	1,765	716	1,199	2.19	2013	259
trastuzumab	3,378	731	572	570	4.75	2005	241
bevacizumab	2,765	308	572	908	3.89	2007	230
dasatinib	1,817	594	524	725	2.56	2011	227
pertuzumab	986	572	570	205	1.39	2013	164
erlotinib	1,172	27	24	205	1.65	2005	84
sunitinib	839	1,765	165	716	1.18	2006	65
gefitinib	1,009	27	24	205	1.42	2003	63
ramucirumab	248	570	528	24	0.35	2015	62
ceritinib	205	205	268	308	0.29	2015	51
blinatumomab	153	725	1,903	360	0.22	2015	38
nivolumab	136	350	1,141	27	0.19	2015	34
ruxolitinib	185	544	594	566	0.26	2013	31
osimertinib	67	496	1,068	205	0.09	2016	22
crizotinib	166	965	722	1,345	0.23	2011	21
ipilimumab	79	350	716	722	0.11	2014	16
ibrutinib	73	306	314	528	0.10	2014	15
lenvatinib	51	210	205	268	0.07	2015	13
brentuximab vedotin	40	24	1,615	44	0.06	2013	7
vemurafenib	30	27	205	1,361	0.04	2012	4
cobimetinib	8	716	724	27	0.01	2017	4
vandetanib	17	27	425	722	0.02	2013	3
pembrolizumab	7	309	165	572	0.01	2015	2
axitinib	12	481	183	205	0.02	2012	2
daratumumab	3	1,290	528	0	0.00	2017	2
Total	71,102	16,855	14,920	14,200	100.00

^†Top 3 adverse events: the reported number of rash, acne, and nausea respectively which are the most frequently reported ADEs on cetuximab.

*Per-Year AE Reports: the numbers were generated by WHO-UMC Custom Search results.

ADE, adverse drug events; AE, adverse events